The T-cell redirecting bispecific antibody teclistamab-cqyv demonstrated efficacy and a tolerable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma consistent with that of those enrolled in the phase 2 MajesTEC-1 trial.
A recent study demonstrated that esketamine nasal spray, used in conjunction with standard antidepressants, could significantly improve outcomes in patients with treatment-resistant depression.
An experimental HIV vaccine trial that took place in Uganda, Tanzania and South Africa was halted after preliminary data suggested it wasn't effective.
Johnson & Johnson Vs. Pfizer: Better Pharma Stock? (NYSE:JNJ) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a type II extension of indication application to the European Medicines Agency (EMA) seeking approval of RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced no.